In reply [6]

Journal of Clinical Oncology

Volumn 23, Issue 28, 2005, Pages 7233-7235

  Movsas, Benjamin ^a   Scott, Charles ^a   Langer, Corey ^a   Werner Wasik, Maria ^a   Nicolaou, Nicos ^a   Machtay, Mitchell ^a   Smith, Colum ^a   Axelrod, Rita ^a   Sarna, Linda ^a   Wasserman, Todd ^a   Byhardt, Roger ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; DRUG METABOLITE;

ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DYSPHAGIA; ESOPHAGITIS; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; MAXIMUM ALLOWABLE CONCENTRATION; NONHUMAN; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 33847034464     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.3572     Document Type: Letter

References (7)

1. Movsas B, Scott C, Langer C, et al: Randomized trial of amifostine in locally advanced non-small cell lung cancer (NSCLC) patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group (RTOG) 98-01. J Clin Oncol 23:2145-2154, 2005
2. Bachy CM, Fazenbaker CA, Kifle G, et al: Daily dosing with amifostine is necessary for full protection against oral mucositis caused by fractionated radiation in rats: Protection and pharmacokinetics. Proc Am Soc Clin Oncol 22:517, 2003 (abstr 2081)
3. Komaki R. Lee JS, Milas L, et al: Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell-lung cancer: Report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58:1369-1377, 2004
4. Bachy C, Fazenbaker C, Kifle G, et al: Tissue levels of WR-1065, the active metabolite of Amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys. Oncology 67:187-193, 2004
5. Cassatt D, Fazenbaker C, Kifle G, et al: Subcutaneous administration of amifostine (Ethyol) is equivalent to intravenous administration in a rat mucositis model. Int J Radiat Oncol Biol Phys 57:794-802, 2003
6. Murley JS, Kataoka Y, Weydert CJ, et al: Delayed cytoprotection after enhancement of Sod2 (mnSOD) gene expression in SA-NH mouse sarcoma cells exposed to WR-1065, the active metabolite of amifostine. Radiat Res 158:101-109, 2002
7. Buntzel J, Frohlich D, Kuttner K, et al: Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head and neck cancer. Ann Oncol 9:505-509, 1998